Browsing by Author "Brangsch, Julia"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Assessment of Albumin ECM Accumulation and Inflammation as Novel In Vivo Diagnostic Targets for Multi-Target MR Imaging
    (2021) Möckel, Jana; Brangsch, Julia; Reimann, Carolin; Kaufmann, Jan O.; Sack, Ingolf; Mangarova, Dilyana B.; Avan, Kader; Taupitz, Matthias; Adams, Lisa C.; Keller, Sarah; Antje, Ludwig; Hamm, Bernd; Botnar, René Michael; Makowski, Marcus R.
  • Thumbnail Image
    Item
    Contrast-Enhanced Magnetic Resonance Angiography Using a Novel Elastin-Specific Molecular Probe in an Experimental Animal Model
    (2018) Reimann, Carolin; Brangsch, Julia; Kaufmann, Jan Ole; Adams, Lisa C.; Onthank, David C.; Robinson, Simon P.; Botnar, René Michael; Collettini, Federico; Makowski, Marcus R.
  • Thumbnail Image
    Item
    Dual-probe molecular MRI for the in vivo characterization of atherosclerosis in a mouse model : Simultaneous assessment of plaque inflammation and extracellular-matrix remodeling
    (2019) Reimann, Carolin; Brangsch, Julia; Kaufmann, Jan Ole; Adams,Lisa C.; Onthank, David C.; Thöne Reineke, Christa; Robinson, Simon P.; Hamm, Bernd; Botnar, René Michael; Makowski, Marcus R.
  • Thumbnail Image
    Item
    Molecular MR-Imaging for Noninvasive Quantification of the Anti-Inflammatory Effect of Targeting Interleukin-1β in a Mouse Model of Aortic Aneurysm
    (SAGE Publications Inc., 2020) Brangsch, Julia; Reimann, Carolin; Kaufmann, Jan Ole; Adams, Lisa Christine; Hamm, Bernd; Makowski, Marcus Richard; Thöne-Reineke, Christa; Wilke, Marco; Weller, Michael; Onthank, David; Robinson, Simon; Buchholz, Rebecca; Karst, Uwe; Botnar, Rene Michael
    Molecular-MRI is a promising imaging modality for the assessment of abdominal aortic aneurysms (AAAs). Interleukin-1β (IL-1β) represents a new therapeutic tool for AAA-treatment, since pro-inflammatory cytokines are key-mediators of inflammation. This study investigates the potential of molecular-MRI to evaluate therapeutic effects of an anti-IL-1β-therapy on AAA-formation in a mouse-model. Methods: Osmotic-minipumps were implanted in apolipoprotein-deficient-mice (N = 27). One group (Ang-II+01BSUR group, n = 9) was infused with angiotensin-II (Ang-II) for 4 weeks and received an anti-murine IL-1β-antibody (01BSUR) 3 times. One group (Ang-II-group, n = 9) was infused with Ang-II for 4 weeks but received no treatment. Control-group (n = 9) was infused with saline and received no treatment. MR-imaging was performed using an elastin-specific gadolinium-based-probe (0.2 mmol/kg). Results: Mice of the Ang-II+01BSUR-group showed a lower aortic-diameter compared to mice of the Ang-II-group and control mice (p < 0.05). Using the elastin-specific-probe, a significant decrease in elastin-destruction was observed in mice of the Ang-II+01BSUR-group. In vivo MR-measurements correlated well with histopathology (y = 0.34x-13.81, R2 = 0.84, p < 0.05), ICP-MS (y = 0.02x+2.39; R2 = 0.81, p < 0.05) and LA-ICP-MS. Immunofluorescence and western-blotting confirmed a reduced IL-1β-expression. Conclusions: Molecular-MRI enables the early visualization and quantification of the anti-inflammatory-effects of an IL-1β-inhibitor in a mouse-model of AAAs. Responders and non-responders could be identified early after the initiation of the therapy using molecular-MRI.